A randomized trial of the effects of ambient light on the incidence of retinopathy (ROP). † 954

Lopes, José M. A.; Braz, R R T; Moreira, Maria Elizabeth E.L.; Motta, Mario; Carvalho, Manoel de; Rebello, Albert; Chemtob, Sylvan; Aranda, Jacob V.

doi:10.1203/00006450-199704001-00973

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each study concluded that there was no statistically significant difference in the incidence of ROP between the two groups. One study included in the metaanalysis by Phelps and Watts (8) (Lopes et al [12]) was excluded from the present review because it was only published in abstract form, and another (13) was excluded because it was published before the period included in the search strategy.…”

Section: Resultsmentioning

confidence: 99%

Does reducing light exposure decrease the incidence of retinopathy of prematurity in premature infants?

Johannes

Dow

2013

Paediatrics &Amp; Child Health

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Does reducing light exposure decrease the incidence of retinopathy of prematurity in premature infants?

Johannes

Dow

2013

Paediatrics &Amp; Child Health

View full text Add to dashboard Cite

“…Davis et al [3]have calculated from their patient population that an ideal treatment which halts lung decline studied over 4 years would require a minimum of 60 patients in each group to detect a statistically significant change. The numbers required are dependent on the severity of lung disease and the age.…”

Section: Discussionmentioning

confidence: 99%

A Case-Controlled Study with Dornase Alfa to Evaluate Impact on Disease Progression over a 4-Year Period

et al. 2001

View full text Add to dashboard Cite

Background: Chronic endobronchial sepsis and profuse airway secretions dominate pulmonary disease in cystic fibrosis. Recombinant human DNase I (dornase alfa) reduces the viscoelasticity of airway secretions and hence may improve clearance of airway secretions. Objectives: To evaluate the long-term influence of dornase alfa on disease progression by performing a case-controlled study with dornase alfa over a period of 4 years. Methods: A cohort of patients with cystic fibrosis who have been treated with dornase alfa were matched with a control group of patients with cystic fibrosis who had not received treatment with dornase alfa. The patients were matched by pulmonary function, age, and then sex. All available measurements of forced expiratory volume in one second (FEV₁), height, weight and sputum bacteriology were collected for periods when the patients were free from respiratory exacerbations. Results: Thirty-eight patients were matched. Slopes of median changes in FEV₁ were –2.19 (–3.32, –1.06) in the control group and –0.75 (–1.87, 0.36) in the dornase alfa-treated group (p = 0.076). There were more infective exacerbations per patient year in the control group [3.13 (1.25–4.25)] in comparison to the dornase alfa group [1.25 (0.63–3.0), p = 0.035] over the 4-year treatment period. Antibiotic requirements were also greater with a median 43.75 (17.5–60.0) days of intravenous antibiotic use per patient year in the control group and 16.25 (8.5–44.0) days in the dornase alfa group (p = 0.034). Conclusions: The trends suggest that dornase alfa may have some influence on disease progression but in view of the limitations of the current study the need for further long-term studies in larger cohorts of patients is emphasised.

show abstract

“…Lung function is a primary indicator of health for people with CF whether measured as Forced Expiratory Volume (FEV1), forced vital capacity (FVC), or FEV1 percent predicted. FEV1-measured using a spirometer-is the volume of air that can be forced out of the lungs in the first second after a full inspiration and is a common marker of disease severity for CF patients (American Thoracic Society, 2005;Davis et al, 1997;Ramsey and Boat, 1994). Two other measures of lung function are; (1) FVC, the volume of air that a patient is able to expire after full inspiration (2) FEV1 percent predicted, the percent of a nonsmoking population normalized for gender, height, age and ethnicity.…”

Section: Introductionmentioning

confidence: 99%

Quantifying Disease Severity Of Cystic Fibrosis Using Quantile Regression Methods

Denaro¹,

Bailey²,

Conrad³

2021

Journal of Data Science

View full text Add to dashboard Cite

This article presents a classification of disease severity for patients with cystic fibrosis (CF). CF is a genetic disease that dramatically decreases life expectancy and quality. The disease is characterized by polymicrobial infections which lead to lung remodeling and airway mucus plugging. In order to quantify disease severity of CF patients and compute a continuous severity index measure, quantile regression, rank scores, and corresponding normalized ranks are calculated for CF patients. Based on the rank scores calculated from the set of quantile regression models, a continuous severity index is computed for each CF patient and can be considered a robust estimate of CF disease severity.

show abstract

A randomized trial of the effects of ambient light on the incidence of retinopathy (ROP). † 954

Cited by 7 publications

References 0 publications

Does reducing light exposure decrease the incidence of retinopathy of prematurity in premature infants?

Does reducing light exposure decrease the incidence of retinopathy of prematurity in premature infants?

A Case-Controlled Study with Dornase Alfa to Evaluate Impact on Disease Progression over a 4-Year Period

Quantifying Disease Severity Of Cystic Fibrosis Using Quantile Regression Methods

Contact Info

Product

Resources

About